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Abstract: The chronic low-grade inflammation in adipose tissue plays a causal role in obesity-
induced insulin resistance and its associated pathophysiological consequences. In this study, we 
investigated the effects of extracts of Broussonetia papyrifera root bark (PRE) and its bioactive 
components on inflammation and insulin sensitivity. PRE inhibited TNF-α-induced NF-κB 
transcriptional activity in the NF-κB luciferase assay and pro-inflammatory genes’ expression by 
blocking phosphorylation of IκB and NF-κB in 3T3-L1 adipocytes, which were mediated by 
activating AMPK. Ten-week-high fat diet (HFD)-fed C57BL6 male mice treated with PRE had 
improved glucose intolerance and decreased inflammation in adipose tissue, as indicated by 
reductions in NF-κB phosphorylation and pro-inflammatory genes’ expression. Furthermore, PRE 
activated AMP-activated protein kinase (AMPK) and reduced lipogenic genes’ expression in both 
adipose tissue and liver. Finally, we identified broussoflavonol B (BF) and kazinol J (KJ) as bioactive 
constituents to suppress pro-inflammatory responses via activating AMPK in 3T3-L1 adipocytes. 
Taken together, these results indicate the therapeutic potential of PRE, especially BF or KJ, in 
metabolic diseases such as obesity and type 2 diabetes. 
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1. Introduction 
Inflammation is a protective response against infection, tissue stress, and injury in any tissue 
and defends and restores physiological functions. However, dysregulated inflammatory processes 
result in chronic inflammation, which is increasingly seen as a major driver of numerous diseases 
such as obesity and type 2 diabetes [1]. Obese adipose tissue produces inflammatory cytokines, 
including tumor necrosis factor (TNF)-α, monocyte chemokine protein (MCP)-1, and interleukin (IL)-
6 [1]. Subsequently, the elevated inflammatory stimuli induce the activation of the inhibitor of κB 
(IκB) kinase (IKK)/NF-κB and c-Jun N-terminal kinase (JNK) pathways, which negatively regulate 
insulin action in not only adipose tissue, but also other peripheral tissues, such as liver [2]. Thus, the 
accumulation of pro-inflammatory responses in adipose tissue may be one of the causal factors for 
insulin resistance. A previous study has demonstrated that pro-inflammatory gene expression is 
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elevated in adipose tissue in the early onset of obesity, but in other tissues, such as liver and skeletal 
muscle, there is no differences in the expression of inflammatory gene expressions [3]. Thus, adipose 
tissues appear to act as priming tissues that respond to a high-fat diet (HFD) and initiate 
inflammation in obesity. Therefore, understanding the inflammatory responses in adipose tissues of 
obese individuals is of clinical importance. 
It has been well demonstrated that AMP-activated protein kinase (AMPK) is a master regulator 
for energy sensing, which responds to control energy homeostasis. AMPK can be activated by various 
conditions. Starvation, hypoxia, exercise, and oxidative damages are the main cellular stresses for 
activating AMPK [4]. There are two well-known upstream kinases: liver kinase B1 (LKB1) and 
Ca2+/calmodulin-dependent protein kinase kinase (CaMKK) can activate AMPK via phosphorylation. 
Several reports clearly demonstrated that one of the major roles of AMPK is regulating metabolic 
requirement. For example, AMPK stimulates energy production pathways through fatty acid 
oxidation, mitochondrial biogenesis, and glucose catabolism. On the other hand, it inhibits energy-
consuming pathways, including fatty acids’ synthesis and amino acids’ biogenesis [5]. Thus, 
dysfunctions of AMPK or downstream signaling pathways could result in metabolic diseases, such 
as obesity and type 2 diabetes [4]. 
Interestingly, it has been reported that AMPK could suppress the NF-κB transcriptional activity 
[6]. The activation of AMPK by AICAR (5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside) can 
inhibit colitis [7], autoimmune encephalomyelitis [8], and inflammation after lung injury [9]. In 
contrast, disrupting AMPK-mediated signaling in hematopoietic-derived cells induced the 
infiltration of adipose tissue macrophages (ATMs) and hepatic steatosis [10]. In addition, pro-
inflammatory responses inhibited the activation of AMPK in adipose tissue and induced the 
expression of pro-inflammatory genes in vivo [11]. It has been reported that the infiltration of ATMs 
is significantly increased in AMPKα1−/− mice, and these mice showed increased expression of pro-
inflammatory genes, such as IL-6 or TNF-α, in adipose tissue [12]. Together, these observations that 
AMPK can suppress inflammation have a significant impact on obese-mediated inflammation in 
adipose tissue. 
Paper mulberry (Broussonetia papyrifera) is a deciduous tree that is distributed throughout Asia, 
and its barks, roots, and fruits are used in traditional Chinese medicine. It has been shown that 
Broussonetia papyrifera has anti-tyrosinase and antioxidant activity [13,14] and anti-inflammatory 
activities in cells [15]. Constituents of the roots of this plant, broussochalcone A, kazinol A, and 
kazinol I, have been reported as inhibitors of lipopolysaccharide-induced nitric oxide (NO) 
production by suppressing NF-κB activation in macrophages [16,17]. Moreover, kazinol B, a B. 
papyrifera-derived prenylated flavan, has been shown to inhibit NO production [16]. Interestingly, 
kazinol B enhances glucose uptake via Akt (a serine/threonine kinase) and AMPK activation in 
adipocytes [17]. Collectively, these reports suggest that B. papyrifera might ameliorate inflammation, 
but to what degree it elicits systemic insulin sensitivity, and by what mechanism, remains unclear. In 
the present study, we aimed to demonstrate that roots of B. papyrifera improve pre-established insulin 
resistance and identify major bioactive compounds that modulate obese-associated inflammation in 
adipose tissue. 
2. Materials and Methods 
2.1. Plant Material 
The root bark of B. papyrifera was sampled at Mugo-ri, Gonyang-myeon, Sacheon-si, 
Gyeongsangnam-do, South Korea, in June 23, 2015 (by Dr. Jin-Hyub Paik). The collected raw 
materials were deposited in the Korea Research Institute of Bioscience and Biotechnology (KRIBB) 
and the International Biological Material Center (IBMRC) (KRIBB 0059119) [18]. Of the collected roots, 
only barks were used for obtaining a better yield. 
2.2. Preparation of B. papyrifera Root Bark 
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The target compounds were isolated from dried root bark of B. papyrifera as previously described 
[18]. Briefly, the total B. papyrifera root bark extracts (TPRE, yield 10.05%) were separated by SPOT-II 
MPLC (medium-pressure liquid chromatography) (Gilson, Middleton, WI, USA) using reversed-
phase silica gel (YMC-Pack ODS-AQ HG, 20 × 250 mm, 10 μm, Kyoto, Japan) eluted with MeOH-
H2O to give TPRE Nos. 1–8 (Figures S1A and 1B). Broussoflavonol B and kazinol J were found to be 
components of TPRE No. 6 (PRE) based on the UPLC-PDA-QTof-MS chromatograms (Figure S1C). 
Among these fractions, TPRE No. 6 (PRE) was subjected to a GX-271 (automated liquid handler) 
semipreparative HPLC system (Gilson, Middleton, WI) using a reversed-phase column (YMC-Pack 
ODS-AQ-HG, 10μm) and eluted with the MeOH-H2O gradient system (55% → 100% MeOH, 70 min) 
by 25 repeated injections of the samples (2 g/mL methanol dilutions) to yield four fractions (PRE Nos. 
6–1~6–4). A further preparation.-HPLC procedure was repeated several times using each condition 
(see below). The fraction 6–3–5 (345.1 mg) enriched with broussoflavonol B was further isolated by 
prep.-HPLC (Gilson, Middleton, MA, USA). Broussoflavonol B (44.9 mg) and broussonol D (29.4 mg) 
were isolated using a YMC-Pack pro C8 column. The fraction 6–3–7 enriched with kazinol J was 
further isolated by prep.-HPLC (PLC 2020) with a gradient system of MeOH-H2O, and (-)–(2S)–
kazinol I (7.6 mg), kazinol J (48.7 mg), broussoflavonol C (215.7 mg), and broussonol G (40.6 mg) were 
obtained. The isolated compounds were purified as described previously, and purity the was more 
than 95.0%, as determined by ultra-performance liquid chromatography [18]. Two compounds were 
characterized using spectroscopic data, including 1H, 13C NMR, and HRMS, in comparison with 
previously published data [16,19]. An ACQUITY UPLC™ system (Waters Corporation, Milford, MA, 
USA) equipped with a binary solvent delivery manager and a photodiode array (PDA) was used for 
UPLC (ultra-performance liquid chromatography) analysis. HRMS analysis was performed using an 
ultra-performance liquid chromatography quadrupole time of flight mass spectrometry (UPLC-
QTOF-MS) equipped with an electrospray ionization (ESI) interface (Waters Q-TOF PremierTM, 
Waters Corporation, Milford, MA, USA). The NMR analysis was carried out using a Fourier 
transform (FT)-NMR spectrometer (JEOL ECZ500R, JEOL Ltd., Akishima, Tokyo, Japan) for 1D 
spectra (1H NMR and 13C NMR). The overall processes are described in Figure S1D. All extracts and 
single compounds for the experiments were prepared by dissolving in dimethyl sulfoxide (DMSO, 
Sigma, St. Louis, MO, USA). 
2.3. Cell Culture and Adipocyte Differentiation 
3T3-L1, Raw264.7, and HEK293 cells were obtained from the American Tissue Culture Collection 
(ATCC, Manassas, VA, USA) and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Life 
Technologies, NY, USA) with 10% bovine calf serum (Invitrogen, Gaithersburg , CA, USA) and 10% 
fetal bovine serum (Atlas, CO, USA), respectively. Adipocyte differentiation was induced by treating 
cells with DMEM containing 10% FBS, 0.5 mM isobutylmethylxanthine (IBMX), 1 μM 
dexamethasone, and 850 nM insulin. After 48 h, the medium was replaced every other day with 
DMEM containing 10% FBS and 850 nM insulin. All chemicals for cell culture were obtained from 
Sigma-Aldrich (St. Louis, MO, USA) unless otherwise indicated. After 6–7 days from initiation of 
differentiation (Figure S2A), we treated compounds as indicated concentrations and time. After 
treating fully differentiated adipocytes with PRE, BF, or KJ for 24h, cell morphology was monitored 
by an inverted microscope (ZEISS, Oberkochen, Germany) (Figure S2B). For Oil Red O staining, 
3T3L1 preadipocytes or differentiated 3T3L1 adipocytes treated with/without PRE, BF, or KJ as 
indicated concentrations were stained with the Oil Red O staining kit according to the manufacturer´s 
recommendations (Biovision, Inc., Milpitas, CA, USA). 
2.4. Reporter Gene Assay 
HEK-293 cells were transfected with NF-κB-responsive luciferase reporter (Promega, San Luis 
Obispo, WI, USA) and pRL-Renilla using Lipofectamine 2000 (Invitrogen, Gaithersburg, CA, USA). 
Following an overnight transfection, the cells were treated with PRE, BF, or KJ for 24 h, followed by 
treatment with TNF-α (10 ng/mL) for 6 h. DMSO was used as the vehicle. The cells were harvested, 
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and reporter gene assays were carried out using the Dual-Luciferase kit (Promega, San Luis Obispo, 
WI, USA). Luciferase activity was normalized to Renilla activity. 
2.5. Nitric Oxide Production and Cell Viability in Raw 264 Cells 
Raw 264 macrophages were seeded in 96 well plates (2.0 × 105 cells/mL) and treated with PRE, 
BR or KJ as the indicated concentration with/without lipopolysaccharide (LPS, Sigma, St. Louis, MO, 
USA) for 24 h. For NO production, the amount of NO was calculated by measured nitrate in media 
using Griess reagent according to the manufacturer´s recommendations (Sigma, St. Louis, MO, USA). 
For cell viability, cells were determined using the MTT solution (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide), Sigma, St. Louis, MO, USA) at 0.5 mg/mL. The purple formazan 
crystals were dissolved in DMSO, and the absorbance was recorded on a microplate reader at a 
wavelength of 570 nm. 
2.6. Animal Experiment 
All animal experiments were performed according to the procedures approved by Ulsan 
National Institute of Science and Technology’s Institutional Animal Care and Use Committee 
(UNISTIACUC-19-04). Seven-week-old male C57BL/6J mice (DBL, samsung, Korea) were fed a high 
fat diet (60% kcal fat, D12492, Research Diets Inc., New Brunswick, NJ, USA) for 10 weeks The mice 
were housed (n = 4/cage) and granted free access to food and water. Food and water were changed 
once a week. For glucose tolerance tests (GTT), mice were intraperitoneally (i.p.) injected daily with 
40 mg/kg of PRE or vehicle (saline containing 5% DMSO and 5% Tween 80 (Sigma, St. Louis, MO, 
USA) for 7 days and fasted for 16 h (6 p.m. to 10 a.m.) prior to i.p. injection of D-glucose (2 g/kg body 
weight). PRE solution prepared at 4 mg/mL in saline containing 5% DMSO and 5% Tween 80 was 
injected in an amount of 10 μL/g of body weight. Fasting insulin was determined using the 
ultrasensitive mouse insulin ELISA kit (Crystal Chem., Eik Grove Village, IL, USA). Once mice were 
sacrificed, isolated adipose tissue and liver were weighed and immediately frozen in liquid nitrogen 
and then used for Western blot analysis and gene expression analysis. 
2.7. Histological Analysis 
Liver sections were embedded in paraffin and stained with hematoxylin and eosin (H&E) to 
visualize hepatocytes and lipid droplets in the tissues. Sections were analyzed by an inverted 
microscope (ZEISS, Oberkochen, Germany). 
2.8. Western Blot Analysis 
Each sample (cells or tissues) was lysed with RIPA lysis buffer containing protease and 
phosphatase inhibitor (Sigma-Aldrich, St. Louis, MO, USA). An equal amount of protein was 
separated on SDS-PAGE and transferred onto nitrocellulose membranes (GE Healthcare, Chigago, 
IL, USA). The membranes were blocked in a 5% bovine serum albumin (BSA) blocking buffer and 
incubated with specific primary antibodies for phospho-NF-κB, NF-κB, phospho-IκB, IκB, phospho-
AMPK, AMPK, phospho-ACC, and ACC (Cell signal technology, Danver, MA, USA) at 4 °C 
overnight. The signals were detected using an ECL detection kit (GE Healthcare, Chigago, IL, USA), 
followed by incubation with horseradish peroxidase-conjugated secondary antibodies 
(Thermofisher, Gaithersburg, CA, USA). We quantified the band intensity by using the ImageJ 
program (NIH, Bethesda, MD, USA). 
2.9. Gene Expression 
Total RNA was isolated from cells or tissues using TRIzol reagents (Invitrogen, city, CA, USA). 
The RNA was reverse-transcribed using the ABI reverse transcription kit. Quantitative PCR reactions 
were performed with SYBR green fluorescent dye using an ABI9300 PCR machine. Relative mRNA 
expression was determined by the ∆∆-Ct method normalized to TATA-binding protein (TBP) levels. 
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2.10. Statistical Analysis 
Data were presented as the means +S.E.M. Statistical significance was estimated by an unpaired 
t-test for comparisons between two conditions. A one-way ANOVA was used for comparisons 
between more than two conditions. Dunnett’s post hoc test was used for multiple comparisons. All 
statistics were performed with GraphPad Prism 7.0 software (GraphPad, San Diego, CA, USA). 
3. Results 
3.1. PRE Suppresses TNF-α-Induced NF-κB Activity 
To investigate the effects of PRE on inflammation, we first tested NF-κB transcriptional activity 
of TPRE because NF-κB is an essential regulator of pro-inflammatory response (Figure S1). As shown 
in Figure 1A, TPRE suppressed NF-κB transcriptional activity induced by TNF-α, and it was dose-
dependent. To further evaluate the effect of TPRE for inhibiting NF-κB activity, we partitioned TPRE 
using medium-pressure liquid chromatography into eight sub-fractions (Figure S1), which were then 
used to assay NF-κB transcriptional activity. Of the eight sub-fractions, four fractions significantly 
inhibited NF-κB transcriptional activity induced by TNF-α. Sub-fraction 6 (PRE) had the most potent 
activity for inhibiting NF-κB activation and dose-dependently repressed NF-κB transcriptional 
activity (Figure 1B and Figure 1C). 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR), an 
AMP analog, was used as the positive control for AMPK activation. 
 
Figure 1. The effects of B. papyrifera root bark extracts on TNF-α-induced NF-κB activity. HEK-293 
cells were transfected with the NF-κB-responsive luciferase reporter and pRL-Renilla. The cells were 
treated with total B. papyrifera (total B. papyrifera root bark extracts, TPRE) extracts (A), sub-fractions 
of TPRE (B), Sub-fraction No.6 (PRE), and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) 
as the indicated concentration for 24 h (C), followed by treatment with TNF-α (10 ng/mL) for an 
additional 6 h. The cells were harvested, and luciferase activity was measured. Data are shown as the 
mean±S.E.M. (n = 3) *p < 0.05; **p < 0.001; ***p < 0.0001 compared to TNF- α-only-treated group. 
3.2. PRE Suppresses Pro-Inflammatory Gene Expression in Adipocytes 
Next, we further tested the effect of PRE on inflammatory responses. Differentiated adipocytes 
were treated with TNF-α, and we examined the effects of PRE on the expression of pro-inflammatory 
genes. As shown in Figure 2A, PRE repressed the TNF-α-mediated pro-inflammatory gene, and this 
effect was dose-dependent. Furthermore, PRE blocked lipopolysaccharide (LPS)-induced pro-
inflammatory response in Raw264.7 cells, as previously reported (Figure S3) [18]. AMPK is a well-
known, important inflammatory suppressor, and AMPK signaling critically regulates inflammation 
in many cell types [6]. Therefore, to further investigate the molecular mechanism involved in PRE-
associated repression of the NF-κB signaling pathway, we first tested whether PRE activated AMPK. 
In 3T3-L1 adipocytes, PRE enhanced the phosphorylation of AMPK, while PRE did not affect AMPK 
protein level. This phosphorylation was blocked by compound C, a specific inhibitor of AMPK 
(Figure 2B). Similarly, the phosphorylation of acetyl-CoA carboxylase (ACC), a substrate of AMPK, 
was enhanced by PRE treatment, and its phosphorylation was blocked by compound C treatment. 
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PRE treatment decreased TNF-α-induced phosphorylation of IκB and NF-κB in adipocytes (Figure 
2C). In addition, pretreatment with AICAR specifically inhibited TNF-α-mediated pro-inflammatory 
signaling. Pretreatment with compound C blocked PRE-induced suppression of phosphorylation of 
IκB and NF-κB in 3T3-L1 adipocytes (Figure 2C). Together, these results strongly suggest that PRE 
suppresses TNF-α-mediated pro-inflammatory gene expression by activating AMPK. 
 
Figure 2. The effects of PRE on TNF-α-induced pro-inflammatory gene expression and AMPK 
activation in 3T3-L1 adipocytes. (A) 3T3-L1 adipocytes were pre-incubated with the indicated 
concentration of PRE for 24 h, followed by treatment with 20 ng/mL TNF-α for 5 h. Total RNA was 
isolated, and the mRNA expression level of each gene was analyzed by real time-PCR. Data are shown 
as the mean ± S.E.M. (n = 3) *p < 0.05; **p < 0.001; ***p<0.0001 compared to the TNF-α-only-treated 
group. (B) After 3T3-L1 adipocytes were pre-incubation with/without compound C for 1 h, cells were 
treated with PRE or AICAR for an additional 2 h. The expression of phospho-AMPK, AMPK, 
phospho-ACC, and ACC was analyzed by Western blotting. (C) 3T3-L1 adipocytes were pretreated 
with the indicated concentration of PRE for 24 h and AICAR for 2 h before 20 ng/mL TNF-α treatment 
for 30 min. Compound C (Comp. C) was pretreated for 1h before PRE treatment. The expression of 
phospho-IκB, IκB, phospho-NF-κB, NF-κB, and tubulin was analyzed by Western blotting. 
3.3. PRE Improves Obesity-Associated Systemic Glucose Tolerance 
Next, we determined whether PRE exhibited anti-diabetic activities in vivo. Ten-week-HFD-fed 
C57BL/6 mice were used for a glucose tolerance test (GTT). PRE and glucose were administrated 
intraperitoneally, because the components of PRE have been reported to inhibit alpha-glucosidase to 
exclude the possibility that oral glucose and PRE administration suppress glucose absorption from 
the gut [20]. The PRE-treated group showed increased glucose tolerance compared to that in control 
mice (Figure 3A). Plasma glucose levels in PRE-treated mice, as determined by the area under the 
curve (AUC), were significantly suppressed compared to those of control mice. Furthermore, the 
fasting insulin level showed a tendency to decrease (Figure 3C), suggesting that PRE ameliorates 
obesity-induced glucose intolerance. Body weight (Figure 3B), adipose tissue weight (Figure S4A), 
and liver weight (Figure S4B) were not changed by treatment with PRE. 
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Figure 3. PRE improved glucose tolerance in diet-induced obese (DIO) mice. Seven-week-old male 
C57BL/6 mice were fed on HFD for 10 weeks, and then PRE was intraperitoneally administrated for 
a week. (A) Intraperitoneal glucose tolerance test (IPGTT) was performed as described in the 
experimental section. Body weight (B) and fasting insulin (C) levels were measured at the end of the 
experiment. Data are shown as the mean ± S.E.M (n = 6) *p < 0.05; **p < 0.001; ***p < 0.0001 vs. HFD-
fed vehicle group; AUC: area under the curve. 
3.4. PRE Ameliorates Adipose Tissue Inflammation 
Our initial results showed that PRE activated AMPK and suppressed pro-inflammatory 
mediators in vitro. Therefore, we tested whether PRE activated AMPK and NF-κB in obese adipose 
tissue in vivo. Upon treatment with PRE, NF-κB phosphorylation was significantly decreased, 
whereas AMPK phosphorylation was increased in epididymal white adipose tissue (eWAT) (Figure 
4A). Next, we assessed the effects of PRE on inflammation in adipose tissue. As shown in Figure 4B, 
the expression of pro-inflammatory genes (Il-1β and inducible nitric oxide synthase (iNOS)) was 
significantly reduced in eWAT after treatment with PRE. However, marker genes of macrophages 
(F4/80, cd11b, and cd68) or marker genes of the M2 macrophage, including arginase-1 (Arg-1), 
mannose receptor C-type 1 (Mrc-1), macrophage galactose binding lectin (Mgl), and Ym-1 (chitinase-
like 3) were not changed (Figure S5). Interestingly, PRE-treated HFD-fed mice showed significantly 
decreased expression of lipogenic genes (fatty acid synthase (Fasn), sterol regulatory element-binding 
protein 1 (Srebp-1c), and Acc-1) in adipose tissue (Figure 4C). These results indicated that PRE had 
anti-inflammatory and anti-lipogenic activities in adipose tissue. 
 
Figure 4. PRE ameliorated adipose tissue inflammation. Adipose tissue was isolated from DIO mice 
in the non-fasted state. (A) The extracts were analyzed with phospho-NF-κB, NF-κB, phospho-AMPK, 
AMPK, and tubulin by Western blot. A.U., arbitrary units. Data are shown as the mean±S.E.M. (n = 4) 
*p < 0.05; **p < 0.001; ***p < 0.0001 vs. HFD-fed vehicle group. The mRNA levels of pro-inflammatory 
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genes (B) and lipogenic genes (C) were analyzed by quantitative real-time PCR. Data are shown as 
the mean±S.E.M. (n = 5) *p < 0.05; **p < 0.001; ***p < 0.0001 vs. HFD-fed vehicle group. 
3.5. PRE Ameliorates Hepatic Steatosis 
Next, we examined whether PRE prevented hepatic steatosis, which is increased by obesity. 
Histological observations revealed that PRE significantly suppressed hepatic steatosis in obese mice 
induced by HFD (Figure 5A and Figure S6). Because AMPK plays crucial roles in suppressing hepatic 
steatosis [4] and PRE activated AMPK in adipose tissue, we examined AMPK signaling in liver. As 
shown in Figure. 5B, treatment with PRE increased AMPK phosphorylation in liver. Furthermore, 
PRE significantly decreased lipogenic gene expression (Srebp-1c and stearoyl-CoA desaturase-1 (Scd-
1)) (Figure. 5C). In addition, PRE increased the expression of acyl-CoA synthetase long-chain (Acsl), 
very-long-chain acyl-CoA dehydrogenase (Vlcad), and short-chain acyl-CoA dehydrogenase (Scad), 
which are involved in fatty acid oxidation (Figure. 5D). Taken together, these results suggested that 
PRE activated AMPK, which improved fatty liver. 
 
Figure 5. PRE ameliorated hepatic steatosis. Liver was isolated from vehicle- or PRE-treated DIO mice 
in the non-fasted state. (A) Liver sections for H&E staining (the scale bar is 125 μm). (B) The extracts 
were analyzed with phospho-AMPK, AMPK, and tubulin by Western blot. Data are shown as the 
mean ± S.E.M (n = 4) *p < 0.05; **p < 0.001; ***p < 0.0001 vs. HFD-fed vehicle group. The mRNA levels 
of lipogenic genes (C) and fatty acid oxidation related genes (D) were analyzed by quantitative real-
time PCR. Data are shown as the mean ± S.E.M (n = 6) *p < 0.05; **p < 0.001; ***p < 0.0001 vs. HFD-fed 
vehicle group. 
3.6. Broussoflavonol B and Kazinol J are Bioactive Compounds of PRE 
To identify the bioactive compounds in PRE that activate AMPK, we isolated 20 compounds via 
methanolic extraction (Figure S1). Among them, we found that broussoflavonol B (BF) and kazinol J 
(KJ) dramatically increased AMPK phosphorylation in 3T3-L1 adipocytes (Figure 6A). Both BF and 
KJ increased AMPK and ACC phosphorylation, and compound C significantly blocked them (Figure 
6B). Furthermore, BF and KJ significantly suppressed TNF-α-induced NF-κB transcriptional activity 
(Figure 6C). Consistent with NF-κB activity, treatment with BF and KJ downregulated TNF-α-
stimulated pro-inflammatory gene expression (Il-6, Mcp-1, and iNOS-only in the BF-treated group) 
in adipocytes (Figure 6D). In addition, both BF and KJ decreased IκB degradation and NF-κB 
phosphorylation, and compound C significantly blocked them (Figure 6E). They also suppressed 
LPS-mediated NO production in Raw264.7 (Figure S7). Together, these results strongly indicated that 
BF and KJ were bioactive compounds of PRE and could block an inflammatory response through 
blocking the NF-κB signaling pathway via AMPK activation. 
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Figure 6. Broussoflavonol B (BF) and kazinol J (KJ) are bioactive compounds of PRE. (A) Chemical 
structure of Broussoflavonol B (top) and kazinol J (bottom). (B) 3T3-L1 adipocytes were pre-incubated 
with/without compound C (10 μM) for 1 h, and then, cells were treated with BF or KJ for an additional 
2 h. The expression of phospho-AMPK, AMPK, phospho-ACC, and ACC was analyzed by Western 
blotting. (C) HEK-293 cells were transfected with the NF-κB-responsive luciferase reporter and pRL-
Renilla. The cells were treated with BF and KJ as the indicated concentration for 24 h, followed by 
treatment with TNF-α (10 ng/mL) for an additional 6 h. The cells were harvested, and luciferase 
activity was measured. Data are shown as the mean ± S.E.M (n = 3) *p < 0.05; **p < 0.001; ***p < 0.0001 
vs. the TNF-α-only-treated group. (D) After 3T3-L1 adipocytes were pretreated with/without 
compound C, cells were incubated with/without BF or KJ for 24 h and stimulated with TNF-α(20 
ng/mL) for 30 min. The expressions of phospho-IκB, IκB, phospho-NF-κB, NF-κB, and tubulin were 
analyzed by Western blotting. (E) 3T3-L1 adipocytes were pre-incubated with the indicated 
concentration of BF or KJ for 24 h, followed by treatment with 20 ng/mL TNF-α for 5 h. Total RNA 
was isolated, and the mRNA expression level of each gene was analyzed by quantitative real-time 
PCR. Data are shown as the mean ± S.E.M (n = 3) *p < 0.05; **p < 0.001; ***p < 0.0001 vs. the TNF-α-
only-treated group. 
4. Discussion 
Obesity is very closely related to chronic and low-grade inflammation. Many reports have 
suggested that insulin resistance accompanies chronic inflammation and abnormal mediator 
secretion in obese adipose tissue [21], indicating that reduction of tissue inflammation could be an 
indispensable target for improving obesity-related metabolic syndromes. It has been reported that 
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roots of B. papyrifera have been used as a suppressant for edema in traditional Chinese medicine [22]. 
The core phytochemicals in the roots of B. papyrifera are flavonols, flavans, and chalcones [23]. There 
is emerging evidence that these core phytochemicals have anti-inflammatory activities. [15,16,24]. In 
the present study, we focused on the anti-inflammatory effects of PRE in adipose tissue and 
investigated whether it could ameliorate systemic insulin resistance in obese mice. PRE potently 
inhibited TNF-α-induced inflammatory responses by suppressing NF-κB activation in adipocytes. 
This effect improved not only glucose tolerance, but also hepatic steatosis in HFD-induced obese 
mice. Using the FDA guideline to calculate human equivalent doses (HED), the HED of this effective 
dose of PRE (40 mg/kg) was 195 mg/day in humans. This dose was lower than that of metformin (850 
mg~2550mg/day) even though PRE was a crude extract. Furthermore, BF and KJ, the isolated 
phytochemicals from PRE, were the bioactive compounds that suppressed inflammatory responses 
in 3T3-L1 adipocytes through blocking NF-κB signaling. Of significance, these effects were partially 
dependent on AMPK activation in adipocytes (Figure S8). 
AMPK has been shown to have strong anti-inflammatory activity via inhibiting inflammatory 
responses in various in vivo models [6]. Various studies have shown that AMPK inhibits pro-
inflammatory signaling in many tissues and cells, especially adipocytes and macrophages, which are 
the main cell types of adipose tissue [25,26]. In addition, AMPK ameliorates insulin resistance in 
obesity [10,11,25,26]. It has been reported that AMPK activators specifically suppressed the 
expression of pro-inflammatory genes and the activation of NF-κB-mediated signaling [27,28]. The 
molecular mechanism for NF-κB activation is: (1) the degradation of IκB in a ubiquitin-dependent 
manner is triggered through its phosphorylation by IKK; (2) IκB degradation results in nuclear 
translocation of NF-κB [29]. Based on these results, we proposed the roles of PRE and its constituents 
to inhibit NF-κB transcriptional activity through the blockade of phosphorylation-mediated IκB 
degradation and NF-κB phosphorylation; this effect was reversed by inhibition of AMPK. Thus, PRE-
mediated NF-κB inactivation would likely be accompanied by inhibition of the TNF-α-stimulated 
IKK/IκB/NF-κB signaling pathway. In addition to the identified signaling pathways, it remains to be 
elucidated whether other molecular mechanisms for the AMPK-mediated anti-inflammatory effect 
of PRE exist. AMPK has several phosphorylation targets [30], but there are some reports suggesting 
that AMPK could inhibit NF-κB activity and its signaling indirectly via sirtuin 1 (SIRT1) [11], the 
forkhead box O (FoxO) family [30], and peroxisome proliferator-activated receptor γ co-activator 
(PGC-1α) [31], which are known as downstream mediators of AMPK. These mediators could 
inactivate the p65 subunit of NF-κB, and the expression of pro-inflammatory genes is subsequently 
repressed. Thus, further studies related to the underlying mechanism of how PRE and its active 
components regulate AMPK activation and its resultant anti-inflammatory effect are needed. 
Obesity-associated adipocyte dysfunction by chronic inflammation in adipose tissue contributes 
to developing hepatic steatosis: (1) excessive free fatty acids from adipose tissue, which stimulate 
inflammation, could be delivered to liver; thus, triglycerides could be accumulated in liver; (2) 
adipose tissue secretes pro-inflammatory cytokines including TNF-α, which exacerbate inflammation 
in liver and induce hepatic steatosis [1] . Here, we demonstrated that PRE did not alter eWAT mass 
and adiposity, by it ameliorated adipose tissue inflammation indicated by significant decreases in the 
pro-inflammatory signaling and pro-inflammatory genes’ expression. Furthermore, PRE enhanced 
AMPK activation, which regulates gene expression related to fatty acid oxidation and lipogenesis. 
Thus, improved adipose tissue inflammation and AMPK activation by PRE could ameliorate hepatic 
steatosis. 
5. Conclusions 
We demonstrated that PRE and its active components had potential therapeutic effects on 
ameliorating inflammation in both adipose tissue and liver. Furthermore, PRE could reduce hepatic 
steatosis and improve glucose homeostasis. In addition, we proposed that the activation of AMPK by 
PRE and its active components could be the underlying molecular mechanism by which they have 
anti-inflammatory effects. Taken together, these finding demonstrated the beneficial effects of B. 
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papyrifera root and its phytochemicals and indicated their potential as candidates for targeting AMPK 
for the treatment of obesity and/or type 2 diabetes. 
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weight, Figure S5: The effect of PRE on macrophage infiltration and polarization in HFD-fed obese mice, Figure 
S6: The effect of PRE in liver steatosis, Figure 7S: The effect of BF and KJ on LPS-induced NO production and 
cell viability in Raw264.7 cells, Figure S8: PRE improves insulin sensitivity via suppressing inflammation by 
activation of AMPK in adipose tissue. 
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